Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
17.03 USD   -2.96%
02/02Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
01/31Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
BU
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

10/27/2022 | 07:03am EST

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Thursday, November 3, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed via this link: https://register.vevent.com/register/BIddf165cd801a473885dd3605fd55f7da.

A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).


ę Business Wire 2022
All news about DECIPHERA PHARMACEUTICALS, INC.
02/02Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
01/31Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Resul..
BU
01/25Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outp..
MT
01/24Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clin..
BU
01/24Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full..
BU
01/24Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase ..
CI
01/23Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
AQ
01/20Deciphera Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Financial St..
AQ
01/20Deciphera Pharmaceuticals Prices $125 Million Common Stock Offering
MT
01/19Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BU
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 133 M - -
Net income 2022 -177 M - -
Net cash 2022 91,0 M - -
P/E ratio 2022 -6,87x
Yield 2022 -
Capitalization 1 284 M 1 284 M -
EV / Sales 2022 8,95x
EV / Sales 2023 7,72x
Nbr of Employees 280
Free-Float 66,0%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 17,03 $
Average target price 21,60 $
Spread / Average Target 26,8%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.7.08%1 284
REGENERON PHARMACEUTICALS, INC.4.12%83 640
VERTEX PHARMACEUTICALS5.19%77 269
WUXI APPTEC CO., LTD.15.80%40 679
BIONTECH SE-5.43%34 523
BEIGENE, LTD.16.80%26 752